Quick Answer
NOVAVAX INC reported Operating Income Loss of $452.80 million for the year ending 2025.
- NOVAVAX INC showed an increase of +281.9% in Operating Income Loss from 2024 to 2025.
- This data is from NOVAVAX INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), NOVAVAX INC's Operating Income Loss has grown by 1,311.2%.
- Historical annual values: Fiscal year 2025: $452.80 million | Fiscal year 2024: -$248.93 million | Fiscal year 2023: -$566.51 million | Fiscal year 2022: -$644.74 million | Fiscal year 2021: -$1.69 billion | Fiscal year 2020: -$416.72 million | Fiscal year 2019: -$120.58 million | Fiscal year 2018: -$173.92 million | Fiscal year 2017: -$171.71 million | Fiscal year 2016: -$269.11 million | Fiscal year 2015: -$157.24 million | Fiscal year 2014: -$83.69 million | Fiscal year 2013: -$52.43 million | Fiscal year 2012: -$29.67 million | Fiscal year 2011: -$21.58 million | Fiscal year 2010: -$38.49 million | Fiscal year 2009: -$37.38 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: